Skip to main content

Page last checked

Symptom question · body composition

Does Ozempic cause muscle loss?

The sources checked here do not show whether Ozempic causes muscle loss. They list side effects, while changes in muscle and lean mass are measured with body scans in separate studies. A blank row here is not proof that muscle mass stays the same.

Source: checked against 36 compound guides; rates are shown exactly as reportedFDA label

This page searches side-effect lists only. It can tell you whether a source calls muscle loss a side effect. It cannot tell you how someone’s body composition changed while losing weight.

Ozempic contains semaglutide. Wegovy and Rybelsus contain the same active ingredient, but they are approved for different uses and come in different forms. The table below groups them under semaglutide.

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Information checked 2026-08-20

At a glance

Compounds that list it

1 of 36

Only in a combined category

1

No published human safety data

11

Best available source

FDA label

Which compounds list muscle loss

The table shows whether each source lists muscle loss as a side effect. Most cells are blank because side-effect sections do not include body-scan results. Do not read a blank cell as proof that no muscle was lost.

◆ Muscle loss across 36 compoundssource shown for every row
Every compound covered on this site, showing whether it lists muscle loss and at what frequency its own cited source states.
CompoundHow it appearsFrequency reportedSource type
TirzepatideZepbound, MounjaroNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaglutideWegovy, Ozempic, RybelsusNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
LiraglutideVictoza, SaxendaNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
RetatrutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
CagrilintideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
SurvodutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
BPC-157No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
TesamorelinEgrifta SV, Egrifta WRMyalgia (muscle pain)counted inside a grouped figure, not on its own6% vs 2% on placebo (26 weeks)FDA label
PT-141VyleesiNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
CJC-1295Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IpamorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
TB-500No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
GHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
SermorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MOTS-cNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
AOD-9604Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
NAD+Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
EpitalonNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Kisspeptin-10No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
DSIPNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
HexarelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IGF-1 LR3No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
PEG-MGFNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
LL-37Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
KPVNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Thymosin alpha-1Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SS-31ForzinityNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaxNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SelankNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Melanotan IINot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MazdutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PinealonNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
AHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
VK2735Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
ZenagamtideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PemvidutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial

A blank result means the label or study checked here does not list the reaction. It does not prove the reaction cannot happen, and it does not replace the full prescribing information. A pharmacist or clinician can review the complete label alongside the rest of a person’s medicines.

3Read deeperWhy it happens, when it appears, and what the page proves

Why a side-effect list cannot answer this question

Side effects and body composition are tracked in different places. Labels list problems reported during treatment. Changes in fat and lean mass need body scans and are usually reported as study results instead.

That means a drug can affect body composition without the words “muscle loss” appearing in its side-effect list. The table below shows what these particular sources contain. It does not prove that no other study has measured lean mass.

Weight loss can include both fat and lean tissue, no matter how the weight is lost. The useful question is how much of each changed, compared with a similar group. Answering that requires a study designed to measure it.

Why appetite still matters

Decreased appetite is also listed for Tirzepatide (common (1–10%)), Liraglutide (reported in Victoza trials (≥5%)), Retatrutide (reported in trials) and Cagrilintide (reported in trials). Each result links to its original source.

Lower appetite can reduce how much someone eats, including protein. These sources do not show what that means for one person’s muscle mass. A clinician or dietitian can look at the person’s diet, activity, weight change and health together.

What a useful study would need to show

A useful answer needs body scans, a clearly described group of people, and results for both fat and lean mass. It also needs a comparison group so readers can see whether the change differs from similar weight loss without the drug.

A percentage by itself can be misleading. It matters how muscle was measured, who was studied, how much weight they lost and what happened in the comparison group.

A body-composition number only makes sense with its scan method, study group, time period and comparison. Without those details, a precise percentage can mislead.

What the evidence shows—and what remains unknown

This page has fewer supported claims than any other in this section. Publishing that honestly is the point of it.

The claimWhat the evidence shows
Muscle loss is a listed side effect of these compounds.Not supported. Side-effect tables do not measure lean mass, so a blank entry is not proof that no muscle was lost.
These compounds do not affect lean mass.Not supported either. These sources contain no body-composition data; missing data is not proof of no change.
Weight lost includes lean tissue as well as fat.General physiology, not a value from these sources. It is true of weight loss by any route, and needs no drug-specific evidence. That is also why it establishes nothing specific about this drug class.
A specific percentage of the weight lost is muscle.Not supported by anything here. A figure like that requires a stated instrument, a defined population and a comparison group. Where those are missing, the number is unusable no matter how precise it looks.
Resistance training or protein intake changes the outcome.Outside these sources entirely, and outside what this page will advise. It is a reasonable question to put to a clinician or a dietitian, who can weigh it against everything else a page cannot see.

When weakness has a listed cause worth checking

Muscle loss is not on these sources. But weakness is a first sign of two reactions that are on them. Both can be found and named rather than blamed on body composition and accepted.

Clinician

Common questions

Is muscle loss listed on the Ozempic or Wegovy label record?

Not in the semaglutide side-effect summary used for both brand names.

It is worth being precise about what that means. The page transcribes the side effects its cited label reports; body composition is not reported in that part of a prescribing document at all. The absence reflects where the question sits rather than what was found.

Is muscle loss on these compounds different from any other weight loss?

That is the important question, and the available side-effect data does not answer it.

Lean tissue moves with weight loss achieved by any route. Whether it moves more, less or the same on this drug class needs a comparison these sources do not contain. A claim in either direction without that comparison is an opinion with a number attached.

Why do other sites give a percentage for muscle loss?

Because a figure reads as authoritative, and the qualifiers that made it meaningful are usually the first thing dropped.

A body-composition figure only makes sense when the scan method, study group and comparison are included. Without those details, an ordinary result can sound dramatic. No percentage is shown here because the side-effect sources do not provide one.

Does decreased appetite explain it?

Decreased appetite is a listed reaction on several records here, so the mechanism people reach for has a documented starting point.

Decreased appetite is documented, but a change in lean mass was not measured in these sources. A clinician or dietitian can assess actual intake and body-composition risk.

Should I take protein supplements or lift weights while taking it?

No cited trial evaluates a training or supplement plan for this purpose, so none is recommended.

It is a reasonable thing to raise at an appointment, particularly alongside anything else on a medicine list. Nothing on this page is a reason to start, stop or change any treatment.

Is feeling weak the same as losing muscle?

No. Muscle loss and sudden weakness are different problems and need different explanations.

Weakness is a first sign of low blood sugar when one of these compounds is taken alongside insulin or a sulfonylurea. It is also a sign of dehydration bad enough to affect the kidneys. Both are listed on these sources, and both can be identified. Filing weakness under expected body-composition change is how a listed and checkable cause gets missed.

How is this different from the hair-loss question?

Both pages report an absence, and the absences are not the same kind.

A side-effect table is built to capture hair loss, and these sources do not carry it. Lean mass is not a side effect; it is a body-composition measurement. A side-effect table would not carry it even if every trial had measured it. The first absence is weak evidence about hair loss; the second tells us nothing about lean mass.

Want the full picture for one compound? Open its guide for uses, dosage information, side effects and serious warnings.

Tirzepatide reactions in full, including muscle loss

Information from an approved label behind tirzepatide, apart from muscle loss.

Every semaglutide reaction, not only muscle loss

9 common and 6 serious semaglutide reactions, in full past muscle loss.

Constipation across every page, as with muscle loss

Which sources name constipation, under what wording and at what frequency, beyond muscle loss.

Nausea read the same way as muscle loss

12 of 36 pages carry nausea, counted class-wide rather than within muscle loss.

Every compound guide, beyond the muscle loss list

Class, approval status and strongest available source for every compound, with muscle loss as one example

Separate lean and fat mass after reading about muscle loss

The calculator keeps measurement uncertainty beside the result, with muscle loss as context

Reading muscle loss for a length nobody published

Three different questions hide inside this one, and each needs a different study, including muscle loss

Tesamorelin reactions in full, including muscle loss

Information from an approved label behind tesamorelin, apart from muscle loss.

The protein ledger that keeps muscle loss claims separate

Muscle loss included only as context: the planner makes no prevention or treatment claim.

Every symptom in this section is listed on the symptom questions index.

Questions readers ask

How do I stop losing muscle on Ozempic?

No cited study evaluates protein, training or another strategy for preventing muscle loss.

These side-effect sources do not measure lean mass. A clinician or dietitian can review actual food intake, strength and the rest of the medicine list.

Why am I losing muscle instead of fat?

These side-effect sources do not measure how weight loss is split between fat and lean tissue, so they cannot confirm the premise.

Weight lost through an energy deficit never comes purely from fat. That is general physiology, true of weight loss by any route, and it was true long before this drug class existed. Whether the split differs on these drugs needs a comparison group none of these sources used.

What are the signs that I'm losing muscle?

Ordinary side-effect tables do not give a symptom checklist for muscle loss. Lean mass is measured with a body scan in a separate study.

Weakness is worth naming for a different reason. It is a first sign of low blood sugar alongside insulin or a sulfonylurea, and of fluid loss bad enough to affect the kidneys. Both are listed on these sources, and both can be found and named.

Can you still build muscle on Ozempic?

No cited study measured whether people could build muscle while taking Ozempic. A useful answer would need body scans, a defined group, a comparison and both fat and lean tissue results.

Decreased appetite is documented, but the effect on protein intake and lean mass was not measured in these sources.

41primary sources, each with the day we read it — open the documents used on this page